Filgotinib

Filgotinib is a pivotal pharmaceutical intermediate and active pharmaceutical ingredient (API) in the treatment of moderate to severe rheumatoid arthritis (RA), and has been extensively investigated in clinical trials for Crohn‘s disease, ulcerative colitis, and other autoimmune conditions. As a JAK1-selective inhibitor, Filgotinib interferes with the phosphorylation of JAK1 and subsequent STAT-dependent signaling, thereby preventing the cytokine-mediated inflammation and immune cell activation that characterizes many autoimmune and inflammatory diseases . The maleate salt form, Filgotinib Maleate (CAS 1802998-75-9), is commonly utilized in pharmaceutical formulations to enhance crystallinity, stability, and handling characteristics, while the free base Filgotinib serves as the active pharmacological agent following oral administration . In quality control and regulatory contexts, Filgotinib and its related substances are essential reference standards for analytical method development, impurity profiling, forced degradation studies, and Abbreviated New Drug Application (ANDA) filings for generic versions. The synthetic route to Filgotinib typically involves a multi-step sequence from readily available starting materials, with published procedures achieving HPLC purity of 99.8% and yields exceeding 88% under optimized conditions . The structural features of Filgotinib — particularly the JAK1-selective triazolopyridine scaffold — continue to inspire medicinal chemistry efforts toward next-generation JAK inhibitors with improved selectivity and safety profiles.

Product Parameters

Mechanism Of Action

Filgotinib selectively inhibits JAK1, thereby reducing the pathogenesis of inflammation and immune-mediated diseases.

Bioactivity

Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 values of 10 nM, 28 nM, 810 nM, and 116 nM against JAK1, JAK2, JAK3, and TYK2, respectively. Phase II clinical trial.

In vivo studies

Following oral administration, the absolute bioavailability in rats was moderate (45%), whereas it was significantly higher in mice (∼100%). In CIA models in both rats and mice, Filgotinib (30 mg/kg/day in rats; 50 mg/kg, twice daily in mice) demonstrated a dose-dependent reduction of inflammation, cartilage damage, and bone degeneration. In studies conducted in DSS-treated mice, results showed that JAK1 inhibition by Filgotinib (GLPG0634) was sufficient to achieve potent therapeutic effects in preclinical mouse models, with this effect correlating with inhibition of STAT3 phosphorylation in inflamed colonic tissues.

Contact Us

Your pursuit of a reliable Filgotinib supply partner for API manufacturing, reference standard needs, or drug development should be straightforward — and with Cosperpharm, it is. We combine scientific rigor, regulatory expertise, and supply chain reliability to deliver the quality you need, when you need it. Contact our customer service team today to discuss your requirements, request a quotation, or schedule a technical consultation.